UA80121C2 - Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease - Google Patents
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease Download PDFInfo
- Publication number
- UA80121C2 UA80121C2 UA20041108994A UA20041108994A UA80121C2 UA 80121 C2 UA80121 C2 UA 80121C2 UA 20041108994 A UA20041108994 A UA 20041108994A UA 20041108994 A UA20041108994 A UA 20041108994A UA 80121 C2 UA80121 C2 UA 80121C2
- Authority
- UA
- Ukraine
- Prior art keywords
- liposomes
- administered
- cholesterol
- days
- disease
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 228
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 48
- 201000010099 disease Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims description 59
- 238000000034 method Methods 0.000 title abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002691 unilamellar liposome Substances 0.000 claims abstract description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 205
- 235000012000 cholesterol Nutrition 0.000 claims description 91
- 238000011282 treatment Methods 0.000 claims description 54
- 201000001320 Atherosclerosis Diseases 0.000 claims description 33
- 230000002411 adverse Effects 0.000 claims description 28
- 208000028867 ischemia Diseases 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 150000003904 phospholipids Chemical class 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 21
- 238000001356 surgical procedure Methods 0.000 claims description 21
- 206010061218 Inflammation Diseases 0.000 claims description 19
- 102000004895 Lipoproteins Human genes 0.000 claims description 19
- 108090001030 Lipoproteins Proteins 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 19
- 230000004054 inflammatory process Effects 0.000 claims description 19
- 208000019553 vascular disease Diseases 0.000 claims description 18
- 208000029078 coronary artery disease Diseases 0.000 claims description 17
- 210000004185 liver Anatomy 0.000 claims description 17
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 230000003511 endothelial effect Effects 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 208000025865 Ulcer Diseases 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 12
- 206010002383 Angina Pectoris Diseases 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 210000004379 membrane Anatomy 0.000 claims description 11
- 208000037803 restenosis Diseases 0.000 claims description 11
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 239000002327 cardiovascular agent Substances 0.000 claims description 10
- 229940125692 cardiovascular agent Drugs 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 10
- 206010021024 Hypolipidaemia Diseases 0.000 claims description 9
- 238000002399 angioplasty Methods 0.000 claims description 9
- 239000003472 antidiabetic agent Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims description 9
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 9
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 229940125708 antidiabetic agent Drugs 0.000 claims description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 7
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 7
- 230000029663 wound healing Effects 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 206010052760 Phlebosclerosis Diseases 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 6
- 208000007718 Stable Angina Diseases 0.000 claims description 6
- 208000007814 Unstable Angina Diseases 0.000 claims description 6
- 206010048215 Xanthomatosis Diseases 0.000 claims description 6
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 230000000391 smoking effect Effects 0.000 claims description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 5
- 208000014882 Carotid artery disease Diseases 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 5
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010033645 Pancreatitis Diseases 0.000 claims description 5
- 206010034576 Peripheral ischaemia Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000017442 Retinal disease Diseases 0.000 claims description 5
- 206010038923 Retinopathy Diseases 0.000 claims description 5
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 206010021198 ichthyosis Diseases 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 210000003141 lower extremity Anatomy 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 230000000250 revascularization Effects 0.000 claims description 5
- 230000002966 stenotic effect Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010043554 thrombocytopenia Diseases 0.000 claims description 5
- 210000004026 tunica intima Anatomy 0.000 claims description 5
- 230000036269 ulceration Effects 0.000 claims description 5
- 210000003462 vein Anatomy 0.000 claims description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 4
- 206010047249 Venous thrombosis Diseases 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 229940125753 fibrate Drugs 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 102000006996 Aryldialkylphosphatase Human genes 0.000 claims description 2
- 108010008184 Aryldialkylphosphatase Proteins 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 claims description 2
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 2
- 208000035868 Vascular inflammations Diseases 0.000 claims description 2
- 206010048214 Xanthoma Diseases 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 230000004768 organ dysfunction Effects 0.000 claims description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 230000001258 dyslipidemic effect Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 150000002823 nitrates Chemical class 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 241000714177 Murine leukemia virus Species 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 description 35
- 238000009826 distribution Methods 0.000 description 24
- 238000001802 infusion Methods 0.000 description 23
- 108010071619 Apolipoproteins Proteins 0.000 description 13
- 102000007592 Apolipoproteins Human genes 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 12
- 238000001125 extrusion Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000002792 vascular Effects 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- 229930182558 Sterol Natural products 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 150000003432 sterols Chemical class 0.000 description 8
- 235000003702 sterols Nutrition 0.000 description 8
- 230000003902 lesion Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241001132374 Asta Species 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000007505 plaque formation Effects 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 4
- 101710097605 Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000003143 atherosclerotic effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000008694 endothelial dysfunction Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000001865 kupffer cell Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 3
- 101710095339 Apolipoprotein E Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 3
- 206010047141 Vasodilatation Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 3
- 230000001346 anti-hypertriglyceridemic effect Effects 0.000 description 3
- 230000002253 anti-ischaemic effect Effects 0.000 description 3
- 230000002930 anti-sclerotic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- -1 cholesterol Chemical class 0.000 description 3
- 150000001840 cholesterol esters Chemical class 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 101150063051 hom gene Proteins 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 208000030175 lameness Diseases 0.000 description 3
- 208000002089 myocardial stunning Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 229920000080 bile acid sequestrant Polymers 0.000 description 2
- 229940096699 bile acid sequestrants Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 102000019758 lipid binding proteins Human genes 0.000 description 2
- 108091016323 lipid binding proteins Proteins 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- NLOGSHMIAWCODV-UHFFFAOYSA-N 2-piperazin-4-ium-1-ylethanesulfonate Chemical compound OS(=O)(=O)CCN1CCNCC1 NLOGSHMIAWCODV-UHFFFAOYSA-N 0.000 description 1
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 244000078127 Eleusine coracana Species 0.000 description 1
- 235000013499 Eleusine coracana subsp coracana Nutrition 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000003867 Phospholipid Transfer Proteins Human genes 0.000 description 1
- 108090000216 Phospholipid Transfer Proteins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- VUBTYKDZOQNADH-UHFFFAOYSA-N acetyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)=O VUBTYKDZOQNADH-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 235000002079 ragi Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002323 scanning near-field ellipsometric microscopy Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37040902P | 2002-04-05 | 2002-04-05 | |
| PCT/US2003/010339 WO2003086351A1 (fr) | 2002-04-05 | 2003-04-04 | Compositions et procedes de dosage de liposomes de certaines tailles pour traiter ou prevenir une maladie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80121C2 true UA80121C2 (en) | 2007-08-27 |
Family
ID=29250522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041108994A UA80121C2 (en) | 2002-04-05 | 2003-04-04 | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20040009216A1 (fr) |
| EP (1) | EP1501482A1 (fr) |
| JP (1) | JP2005527582A (fr) |
| KR (1) | KR20050009988A (fr) |
| CN (1) | CN1655764A (fr) |
| AP (1) | AP2004003157A0 (fr) |
| AU (1) | AU2003230800A1 (fr) |
| BR (1) | BR0309030A (fr) |
| CA (1) | CA2480763A1 (fr) |
| CR (1) | CR7563A (fr) |
| EA (1) | EA007986B1 (fr) |
| EC (1) | ECSP045409A (fr) |
| HR (1) | HRP20040915A2 (fr) |
| IL (1) | IL164370A0 (fr) |
| IS (1) | IS7493A (fr) |
| MA (1) | MA27298A1 (fr) |
| MX (1) | MXPA04009692A (fr) |
| NO (1) | NO20044751L (fr) |
| NZ (1) | NZ535900A (fr) |
| OA (1) | OA12799A (fr) |
| PL (1) | PL372689A1 (fr) |
| RS (1) | RS87704A (fr) |
| TN (1) | TNSN04190A1 (fr) |
| UA (1) | UA80121C2 (fr) |
| WO (1) | WO2003086351A1 (fr) |
| ZA (1) | ZA200407947B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275850A1 (en) * | 2002-10-25 | 2004-05-13 | Vasogen Ireland Limited | Cyclooxygenase regulation with ps liposomes |
| AU2003275842A1 (en) * | 2002-10-25 | 2004-05-13 | Vasogen Ireland Limited | Cyclooxygenase regulation with pg liposomes |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| EA200600297A1 (ru) * | 2003-07-21 | 2006-08-25 | Васоджен Айеленд Лимитед | Лечение острого воспалительного состояния |
| US20080260861A1 (en) * | 2004-04-07 | 2008-10-23 | The General Hospital Corporation | Modulating Lymphatic Function |
| JP2008521818A (ja) * | 2004-11-23 | 2008-06-26 | メデイカル・カレツジ・オブ・ジヨージア | ケラチノサイト機能を調節するための方法および組成物 |
| KR100891595B1 (ko) * | 2005-02-28 | 2009-04-03 | 주식회사 케이티앤지 | 혈액 단백질의 삼출을 감소시키는 조성물 |
| KR100768265B1 (ko) * | 2005-11-10 | 2007-10-17 | 한국화학연구원 | 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법 |
| JP4395658B2 (ja) * | 2005-11-17 | 2010-01-13 | エムジーファーマ株式会社 | コレステロール再上昇抑制用組成物およびその用法 |
| US8697120B2 (en) * | 2006-05-01 | 2014-04-15 | Johns Hopkins University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| CN101484588B (zh) | 2006-05-11 | 2013-11-06 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| CA2713379A1 (fr) * | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Procedes optimises d'administration d'arnds ciblant le gene pcsk9 |
| AU2010223967B2 (en) * | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| SG10201911942UA (en) * | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| CN105434353A (zh) * | 2009-06-03 | 2016-03-30 | 斯昆申技术控股有限责任公司 | 用于治疗深部组织疼痛的制剂 |
| KR101766408B1 (ko) * | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| JP5894913B2 (ja) * | 2009-06-15 | 2016-03-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ |
| WO2011059262A2 (fr) * | 2009-11-13 | 2011-05-19 | 경북대학교 산학협력단 | Utilisations de peptides ciblant des cellules apoptotiques, substances de marquage et liposomes contenant un agent thérapeutique pour prévenir, traiter ou diagnostiquer thérapeutiquement des maladies associées à l'apoptose |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| SG10201709195TA (en) | 2012-11-13 | 2017-12-28 | Nusirt Sciences Inc | Compositions and methods for increasing energy metabolism |
| IL292159B1 (en) | 2012-12-05 | 2026-04-01 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA compositions and methods of using them |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| CN104422750B (zh) * | 2013-09-05 | 2016-02-10 | 中国科学院大连化学物理研究所 | 一种烟叶中磷脂酰乙醇胺与甘油三酯含量的检测方法 |
| EP3095448B1 (fr) * | 2014-01-17 | 2019-03-13 | Nishizaki Bioinformation Research Institute | Inhibiteur d'endocytose de transporteur 4 du glucose |
| CN110279654B (zh) * | 2019-07-22 | 2023-02-03 | 苏州大学附属第一医院 | 缓释阿司匹林脂质体水凝胶、制备方法及其在制备治疗复发性腰椎间盘突出症药物中的应用 |
| CN116528839A (zh) * | 2020-12-04 | 2023-08-01 | 瑞格国际生技股份有限公司 | 药代动力学被改善的含CD1d配体化合物的脂质体制剂 |
| CA3202742A1 (fr) * | 2020-12-22 | 2022-06-30 | Regina E. HERZLINGER | Procedes, systemes et appareil d'administration d'un traitement d'anticorps monoclonal et/ou polyclonal par perfusion rapide |
| US11806507B2 (en) | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| US12133966B2 (en) | 2020-12-22 | 2024-11-05 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
| KR20250114904A (ko) * | 2024-01-22 | 2025-07-29 | 연세대학교 산학협력단 | 단핵구에 탑재되는 리포좀을 포함하는 약물 전달체 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| JPS5348976A (en) * | 1976-10-18 | 1978-05-02 | Nippon Zeon Co Ltd | Mass transfer apparatus of hollow fiber type |
| US4186183A (en) * | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4247393A (en) * | 1979-01-11 | 1981-01-27 | Wallace Richard A | Hemodialysis assist device |
| US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| EP0180720B1 (fr) * | 1981-09-10 | 1990-06-13 | B. Braun-SSC AG | Dispositif pour la précipitation sélective extracorporelle des lipoprotéines à basse densité dans du sérum et du plasma sanguin |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4532089A (en) * | 1984-01-14 | 1985-07-30 | Northwestern University | Method of preparing giant size liposomes |
| US4663167A (en) * | 1984-04-16 | 1987-05-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| US4978654A (en) * | 1984-04-16 | 1990-12-18 | Board Of Regents, The University Of Texas System | Composition and method for treatment of disseminated fungal infections in mammals |
| US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| JPS63500175A (ja) * | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−，インコ−ポレイテツド | リポソ−ム吸入法および吸入システム |
| US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4812314A (en) * | 1986-02-24 | 1989-03-14 | Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization | Lipid replacement therapy |
| US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
| US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
| US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| US5258499A (en) * | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5219994A (en) * | 1988-11-08 | 1993-06-15 | W. Alton Jones Cell Science Center, Inc. | Inhibitor of tissue factor activity |
| US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| EP0469082B1 (fr) * | 1989-04-18 | 1995-04-05 | Vestar, Inc. | Marquage liposomique de tissus ischemiques |
| US5225212A (en) * | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE4018767A1 (de) * | 1990-06-12 | 1991-12-19 | Braun Melsungen Ag | Wirkstofffreie liposomen zur behandlung von atherosklerose |
| US5231090A (en) * | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| US5556637A (en) * | 1990-08-06 | 1996-09-17 | A. Nattermann & Cie. Gmbh | Water containing liposome system |
| JPH04305879A (ja) * | 1990-09-12 | 1992-10-28 | Fuji Electric Co Ltd | ディスク記憶装置のヘッド操作用可動体の拘束装置 |
| US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
| US5405832A (en) * | 1991-11-27 | 1995-04-11 | Immtech International Inc. | Method of treating non-streptococcal bacterial infections |
| US5219888A (en) * | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
| US5250060A (en) * | 1992-06-26 | 1993-10-05 | Carbo Paul L | Angioplasty apparatus |
| US5637315A (en) * | 1993-01-04 | 1997-06-10 | Thomas Jefferson University | Treatment of disease states induced by oxidative stress |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
| US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| US6139871A (en) * | 1995-07-26 | 2000-10-31 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
| US5599306A (en) * | 1994-04-01 | 1997-02-04 | Localmed, Inc. | Method and apparatus for providing external perfusion lumens on balloon catheters |
| US5622715A (en) * | 1994-06-10 | 1997-04-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of improving renal function |
| US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5674488A (en) * | 1994-10-07 | 1997-10-07 | Reich; John J. | Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol |
| CA2206289A1 (fr) * | 1994-11-23 | 1996-05-30 | Kimberly-Clark Worldwide, Inc. | Article absorbant comprenant une partie centrale composite et absorbante |
| US5489611A (en) * | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
| US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5741514A (en) * | 1995-08-31 | 1998-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for reducing serum lipoprotein(a) concentration |
| CA2231547A1 (fr) * | 1995-10-11 | 1997-04-17 | Kevin Jon Williams | Compositions liposomiques et leurs methodes d'utilisation |
| US5846691A (en) * | 1996-07-08 | 1998-12-08 | Polyfibron Technologies, Inc. | Composite relief image printing plates and methods for preparing same |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6410802B1 (en) * | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
| AU773385B2 (en) * | 1999-05-14 | 2004-05-27 | Esperion Luv Development, Inc. | Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| JP2005518266A (ja) * | 2001-09-28 | 2005-06-23 | エスペリオン セラピューティクス，インコーポレイテッド | 高圧でベシクルを押し出す方法および装置 |
-
2003
- 2003-03-31 US US10/403,402 patent/US20040009216A1/en not_active Abandoned
- 2003-04-04 RS YU87704A patent/RS87704A/sr unknown
- 2003-04-04 CA CA002480763A patent/CA2480763A1/fr not_active Abandoned
- 2003-04-04 MX MXPA04009692A patent/MXPA04009692A/es unknown
- 2003-04-04 OA OA1200400268A patent/OA12799A/en unknown
- 2003-04-04 EA EA200401317A patent/EA007986B1/ru not_active IP Right Cessation
- 2003-04-04 PL PL03372689A patent/PL372689A1/xx not_active Application Discontinuation
- 2003-04-04 UA UA20041108994A patent/UA80121C2/uk unknown
- 2003-04-04 HR HR20040915A patent/HRP20040915A2/hr not_active Application Discontinuation
- 2003-04-04 WO PCT/US2003/010339 patent/WO2003086351A1/fr not_active Ceased
- 2003-04-04 EP EP03723897A patent/EP1501482A1/fr not_active Withdrawn
- 2003-04-04 IL IL16437003A patent/IL164370A0/xx unknown
- 2003-04-04 NZ NZ535900A patent/NZ535900A/en unknown
- 2003-04-04 AU AU2003230800A patent/AU2003230800A1/en not_active Abandoned
- 2003-04-04 JP JP2003583374A patent/JP2005527582A/ja active Pending
- 2003-04-04 BR BR0309030-2A patent/BR0309030A/pt not_active IP Right Cessation
- 2003-04-04 CN CNA038125668A patent/CN1655764A/zh active Pending
- 2003-04-04 AP APAP/P/2004/003157A patent/AP2004003157A0/en unknown
- 2003-04-04 KR KR10-2004-7015874A patent/KR20050009988A/ko not_active Ceased
-
2004
- 2004-10-01 ZA ZA200407947A patent/ZA200407947B/en unknown
- 2004-10-04 MA MA27886A patent/MA27298A1/fr unknown
- 2004-10-04 TN TNP2004000190A patent/TNSN04190A1/en unknown
- 2004-10-08 IS IS7493A patent/IS7493A/is unknown
- 2004-11-02 CR CR7563A patent/CR7563A/es not_active Application Discontinuation
- 2004-11-02 NO NO20044751A patent/NO20044751L/no not_active Application Discontinuation
- 2004-11-04 EC EC2004005409A patent/ECSP045409A/es unknown
-
2008
- 2008-02-21 US US12/070,949 patent/US20080213351A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0309030A (pt) | 2005-02-01 |
| ZA200407947B (en) | 2006-07-26 |
| EA007986B1 (ru) | 2007-02-27 |
| IS7493A (is) | 2004-10-08 |
| WO2003086351A1 (fr) | 2003-10-23 |
| EA200401317A1 (ru) | 2005-06-30 |
| US20040009216A1 (en) | 2004-01-15 |
| AP2004003157A0 (en) | 2004-12-31 |
| EP1501482A1 (fr) | 2005-02-02 |
| MXPA04009692A (es) | 2006-03-08 |
| CN1655764A (zh) | 2005-08-17 |
| NZ535900A (en) | 2008-08-29 |
| US20080213351A1 (en) | 2008-09-04 |
| KR20050009988A (ko) | 2005-01-26 |
| RS87704A (sr) | 2006-12-15 |
| CA2480763A1 (fr) | 2003-10-23 |
| CR7563A (es) | 2005-09-20 |
| IL164370A0 (en) | 2005-12-18 |
| MA27298A1 (fr) | 2005-05-02 |
| AU2003230800A1 (en) | 2003-10-27 |
| TNSN04190A1 (en) | 2007-03-12 |
| ECSP045409A (es) | 2005-03-10 |
| JP2005527582A (ja) | 2005-09-15 |
| NO20044751L (no) | 2004-12-20 |
| PL372689A1 (en) | 2005-07-25 |
| OA12799A (en) | 2006-07-11 |
| HRP20040915A2 (en) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA80121C2 (en) | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease | |
| JP6964571B2 (ja) | 関節炎の処置方法 | |
| AU773385B2 (en) | Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto | |
| WO2023029041A1 (fr) | Système d'administration de nanoporteurs de liposomes ciblant l'athérosclérose et son procédé de préparation | |
| US5741514A (en) | Method for reducing serum lipoprotein(a) concentration | |
| US6261597B1 (en) | Method for treating periodontal disease | |
| WO2018045015A1 (fr) | Procédés et kits pour réduire la tendance de particules de lipoprotéine à l'agrégation athérogène induite par des enzymes de paroi artérielle | |
| EP0726763A1 (fr) | Procedes de traitement faisant appel a des formulations de metabolite d'acide arachidonique liposomique unilamellaire | |
| US5811118A (en) | Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations | |
| JPH09510220A (ja) | 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のメルカプトアセチルアミド誘導体 | |
| JP2007224032A (ja) | 黄斑変性症及び関連する眼の病気の治療方法 | |
| RU2848053C2 (ru) | Система доставки липосомного наноносителя для таргетной терапии атеросклероза и способ ее получения | |
| HK40102572A (zh) | 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法 | |
| HK40102572B (zh) | 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法 | |
| HK40128812A (zh) | 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法 | |
| HK1219414B (en) | Methods of treating arthritis | |
| JP2004115397A (ja) | 血管疾患治療薬を含むリポソーム |